University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu

Thomas Jefferson University - Michael J. Mastrangelo
Michael J. Mastrangelo

Medical Oncology
Thomas Jefferson University
Jefferson Medical College
Department of Medical Oncology
Professor

Image Placeholder
Mailing Address
1015 Walnut Street, Room 1024
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: (215) 955-8875
Fax: (215) 923-0797
Michael.Mastrangelo@jefferson.edu
Qualifications
M.D.,

Expertise and Research Interests
Areas of clinical and research interests include the biology, diagnosis and treatment of melanoma, and the immunotherapy of bladder and prostate cancer. Melanoma therapies focus on the modulation of drug resistance with tamoxifen and immunotherapy studies are directed toward active specific immunization with whole cells and vaccinia virus recombinants. Both wild-type and recombinant vaccinia viruses are being used intravesically for treatment of bladder cancer. In conjunction with Cel-Sci-Corp, intraprostatic injection of mixed interleukins is being explored as a neoadjuvant therapy in patients with prostate cancer.
Keywords
Cancer; Cancer Biology; Cancer Prevention; Carcinogenesis
Publications
  • Nathan FE; Berd D; Sato T; Mastrangelo MJ. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer. 88(1): 79-87, 1 2000

  • Harris DT; Matyas GR; Gomella LG; Talor E; Winship MD; Spitler LE; Mastrangelo MJ. Immunologic approaches to the treatment of prostate cancer. Seminars in Oncology. 26(4): 439-47, Aug 1999

  • Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC Jr. Autologous, hapten-modified vaccine as a treatment for human cancers. Seminars in Oncology. 25(6): 646-53, Dec 1998

  • Bass K K;Mastrangelo M J. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunology, Immunotherapy. 47(1): 1-12, Sep 1998

  • Nathan F E;Mastrangelo M J. Systemic therapy in melanoma. Seminars In Surgical Oncology. 14(4): 319-27, Jun 1998

  • Gunduz K;Shields J A;Shields C L;Sato T;Mastrangelo M J. Surgical removal of solitary hepatic metastasis from choroidal melanoma. American Journal of Ophthalmology. 125(3): 407-9, Mar 1998

  • Alexander A A;Nazarian L N;Capuzzi D M Jr;Rawool N M;Kurtz A B;Mastrangelo M J. Color Doppler sonographic detection of tumor flow in superficial melanoma metastases: histologic correlation. Journal of Ultrasound In Medicine. 17(2): 123-6, Feb 1998

  • Nazarian L N;Alexander A A;Kurtz A B;Capuzzi D M Jr;Rawool N M;Gilbert K R;Mastrangelo M J. Superficial melanoma metastases: appearances on gray-scale and color Doppler sonography. AJR American Journal of Roentgenology. 170(2): 459-63, Feb 1998

  • Alexander Archie A;Nazarian Levon N;Capuzzi David M;Rawool Nandkumar M;Kurtz Alfred B;Mastrangelo Michael J. Color Doppler sonographic detection of tumor flow in superficial melanoma metastases: Histologic correlation. Journal of Ultrasound in Medicine. 17(2): 123-126, 1998

  • McClay E F;Berd D;Mastrangelo M J. The Dartmouth Regimen: gone or going strong? [editorial; comment]. Cancer Investigation. 16(6): 421-3, 1998

  • Mastrangelo M J;Sato T;Lattime E C;Maguire H C Jr;Berd D. Cellular vaccine therapies for cancer. Cancer Treatment and Research. 94: 35-50, 1998

  • Sato T;Bullock T N;Eisenlohr L C;Mastrangelo M J;Berd D. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clinical Immunology and Immunopathology. 85(3): 265-72, Dec 1997

  • Nathan F E;Berd D;Sato T;Shield J A;Shields C L;De Potter P;Mastrangelo M J. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. Journal of Experimental and Clinical Cancer Research. 16(2): 201-8, Jun 1997

  • Berd D;Maguire H C Jr;Schuchter L M;Hamilton R;Hauck W W;Sato T;Mastrangelo M J. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. Journal of Clinical Oncology. 15(6): 2359-70, Jun 1997

  • Sorensen S C;Garcia-Manero G;Mastrangelo M J;Soltan A. Does lymph node dissection still have a role in cancer therapy?. Seminars In Oncology. 24(3): xxxiii-xxxiv, xxxix,, Jun 1997

  • Sato T;Babazono A;Shields J A;Shields C L;De Potter P;Mastrangelo M J. Time to systemic metastases in patients with posterior uveal melanoma. Cancer Investigation. 15(2): 98-105, 1997

  • Mastrangelo M J;Maguire H C Jr;Sato T;Nathan F E;Berd D. Active specific immunization in the treatment of patients with melanoma. Seminars In Oncology. 23(6): 773-81, Dec 1996

  • Sato T; McCue P; Masuoka K; Salwen S; Lattime EC; Mastrangelo MJ; Berd D. Interleukin 10 production by human melanoma. Clinical Cancer Research. 2(8): 1383-90, Aug 1996

  • Berd D;Mastrangelo M J;Lattime E;Sato T;Maguire H C Jr. Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunology, Immunotherapy. 42(5): 263-7, Jun 1996

  • Nazarian L N;Alexander A A;Rawool N M;Kurtz A B;Maguire H C;Mastrangelo M J. Malignant melanoma: impact of superficial US on management. Radiology. 199(1): 273-7, Apr 1996

  • Ohta M;Berd D;Shimizu M;Nagai H;Cotticelli M-G;Mastrangelo M;Shields J A;Shields C L;Croce C M;Huebner K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. International Journal of Cancer. 65(6): 762-7, 15 Mar 1996

  • Lattime E C;Lee S S;Eisenlohr L C;Mastrangelo M J. In situ cytokine gene transfection using vaccinia virus vectors. Seminars In Oncology. 23(1): 88-100, Feb 1996

  • Mastrangelo M J;Berd D;Nathan F E;Lattime E C. Gene therapy for human cancer: an essay for clinicians. Seminars In Oncology. 23(1): 4-21, Feb 1996

  • Nathan F E;Mastrangelo M J. Adjuvant therapy for cutaneous melanoma. Seminars In Oncology. 22(6): 647-61, Dec 1995

  • Somasundaram R;Zaloudik J;Jacob L;Benden A;Sperlagh M;Hart E;Marks G;Kane M;Mastrangelo M;Herlyn D. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. Journal of Immunology. 155(6): 3253-61, 15 Sep 1995

  • Lattime E C;Mastrangelo M J;Bagasra O;Li W;Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunology, Immunotherapy. 41(3): 151-6, Sep 1995

  • Berd D;Mastrangelo M J. Combination chemotherapy of metastatic melanoma [letter; comment]. Journal of Clinical Oncology. 13(3): 796-7, Mar 1995

  • Sato T;Maguire H C Jr;Mastrangelo M J;Berd D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clinical Immunology and Immunopathology. 74(1): 35-43, Jan 1995

  • Ohta M;Nagai H;Shimizu M;Rasio D;Berd D;Mastrangelo M;Singh A D;Shields J A;Shields C L;Croce C M;et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Research. 54(20): 5269-72, 15 Oct 1994

  • Berd D;Maguire H C Jr;Mastrangelo M J;Murphy G. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunology, Immunotherapy. 39(3): 141-7, Sep 1994

  • Lee S S;Eisenlohr L C;McCue P A;Mastrangelo M J;Lattime E C. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Research. 54(13): 3325-8, 1 Jul 1994

  • Herlyn D;Somasundaram R;Zaloudik J;Jacob L;Harris D;Kieny M P;Sears H;Mastrangelo M. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophysics. 24-25: 143-53, 1994

  • Berd D;Maguire H C Jr;Mastrangelo M J. Treatment of human melanoma with a hapten-modified autologous vaccine. Annals of The New York Academy of Sciences. 690: 147-52, 12 Aug 1993

  • McLaughlin C;Maguire H C Jr;Mastrangelo M J. Natural history of a superficial spreading melanoma. International Journal of Dermatology. 32(4): 293-6, Apr 1993

  • McClay E F;Mastrangelo M J;Berd D;Bellet R E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. International Journal of Cancer. 50(4): 553-6, 20 Feb 1992

  • Harris D T;Mastrangelo M J. Theory and application of early systemic therapy. Seminars In Oncology. 18(6): 493-503, Dec 1991

  • Berd D;Murphy G;Maguire H C Jr;Mastrangelo M J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Research. 51(10): 2731-4, 15 May 1991

  • Slovin S F;Maguire H C Jr;Mastrangelo M J. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro. Cancer. 66(12): 2541-6, 15 Dec 1990

  • McLean I W;Berd D;Mastrangelo M J;Shields J A;Davidorf F H;Grever M;Makley T A;Gamel J W. A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. American Journal of Ophthalmology. 110(5): 522-6, 15 Nov 1990

  • Berd D;Maguire H C Jr;McCue P;Mastrangelo M J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. Journal of Clinical Oncology. 8(11): 1858-67, Nov 1990

  • Schultz S;Kane M;Roush R;Miller V;Berd D;Goldman L;Mastrangelo M. Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma. Surgery, Gynecology and Obstetrics. 171(5): 393-7, Nov 1990

  • Schultz S;Mastrangelo M J. The pathophysiology and staging of cutaneous malignant melanoma. Seminars In Oncology. 16(1 Suppl 1): 27-33, Feb 1989

Individual Expertise profile of Michael J. Mastrangelo, Copyright © Michael J. Mastrangelo.
Last Updated by Admin : Monday, January 8, 2007 3:56:16 PM



Maintained by Jefferson Information Technologies
Copyright © Thomas Jefferson University. All Rights Reserved.

 Printable Version

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement.
Thomas Jefferson University